James F Sumowski1, Maria A Rocca2, Victoria M Leavitt2, Jelena Dackovic2, Sarlota Mesaros2, Jelena Drulovic2, John DeLuca2, Massimo Filippi2. 1. From Neuropsychology and Neuroscience (J.F.S., J. DeLuca), Kessler Foundation Research Center, West Orange; Rutgers (J.F.S., J. DeLuca), New Jersey Medical School, Newark, NJ; Neuroimaging Research Unit (M.A.R., M.F.) and Department of Neurology (M.A.R., M.F.), San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Manhattan Memory Center (V.M.L.), New York, NY; and Clinic of Neurology (J. Dackovic, S.M., J. Drulovic), Faculty of Medicine, University of Belgrade, Serbia. jsumowski@kesslerfoundation.org. 2. From Neuropsychology and Neuroscience (J.F.S., J. DeLuca), Kessler Foundation Research Center, West Orange; Rutgers (J.F.S., J. DeLuca), New Jersey Medical School, Newark, NJ; Neuroimaging Research Unit (M.A.R., M.F.) and Department of Neurology (M.A.R., M.F.), San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Manhattan Memory Center (V.M.L.), New York, NY; and Clinic of Neurology (J. Dackovic, S.M., J. Drulovic), Faculty of Medicine, University of Belgrade, Serbia.
Abstract
OBJECTIVE: Based on the theories of brain reserve and cognitive reserve, we investigated whether larger maximal lifetime brain growth (MLBG) and/or greater lifetime intellectual enrichment protect against cognitive decline over time. METHODS: Forty patients with multiple sclerosis (MS) underwent baseline and 4.5-year follow-up evaluations of cognitive efficiency (Symbol Digit Modalities Test, Paced Auditory Serial Addition Task) and memory (Selective Reminding Test, Spatial Recall Test). Baseline and follow-up MRIs quantified disease progression: percentage brain volume change (cerebral atrophy), percentage change in T2 lesion volume. MLBG (brain reserve) was estimated with intracranial volume; intellectual enrichment (cognitive reserve) was estimated with vocabulary. We performed repeated-measures analyses of covariance to investigate whether larger MLBG and/or greater intellectual enrichment moderate/attenuate cognitive decline over time, controlling for disease progression. RESULTS: Patients with MS declined in cognitive efficiency and memory (p < 0.001). MLBG moderated decline in cognitive efficiency (p = 0.031, ηp (2) = 0.122), with larger MLBG protecting against decline. MLBG did not moderate memory decline (p = 0.234, ηp (2) = 0.039). Intellectual enrichment moderated decline in cognitive efficiency (p = 0.031, ηp (2) = 0.126) and memory (p = 0.037, ηp (2) = 0.115), with greater intellectual enrichment protecting against decline. MS disease progression was more negatively associated with change in cognitive efficiency and memory among patients with lower vs higher MLBG and intellectual enrichment. CONCLUSION: We provide longitudinal support for theories of brain reserve and cognitive reserve in MS. Larger MLBG protects against decline in cognitive efficiency, and greater intellectual enrichment protects against decline in cognitive efficiency and memory. Consideration of these protective factors should improve prediction of future cognitive decline in patients with MS.
OBJECTIVE: Based on the theories of brain reserve and cognitive reserve, we investigated whether larger maximal lifetime brain growth (MLBG) and/or greater lifetime intellectual enrichment protect against cognitive decline over time. METHODS: Forty patients with multiple sclerosis (MS) underwent baseline and 4.5-year follow-up evaluations of cognitive efficiency (Symbol Digit Modalities Test, Paced Auditory Serial Addition Task) and memory (Selective Reminding Test, Spatial Recall Test). Baseline and follow-up MRIs quantified disease progression: percentage brain volume change (cerebral atrophy), percentage change in T2 lesion volume. MLBG (brain reserve) was estimated with intracranial volume; intellectual enrichment (cognitive reserve) was estimated with vocabulary. We performed repeated-measures analyses of covariance to investigate whether larger MLBG and/or greater intellectual enrichment moderate/attenuate cognitive decline over time, controlling for disease progression. RESULTS:Patients with MS declined in cognitive efficiency and memory (p < 0.001). MLBG moderated decline in cognitive efficiency (p = 0.031, ηp (2) = 0.122), with larger MLBG protecting against decline. MLBG did not moderate memory decline (p = 0.234, ηp (2) = 0.039). Intellectual enrichment moderated decline in cognitive efficiency (p = 0.031, ηp (2) = 0.126) and memory (p = 0.037, ηp (2) = 0.115), with greater intellectual enrichment protecting against decline. MS disease progression was more negatively associated with change in cognitive efficiency and memory among patients with lower vs higher MLBG and intellectual enrichment. CONCLUSION: We provide longitudinal support for theories of brain reserve and cognitive reserve in MS. Larger MLBG protects against decline in cognitive efficiency, and greater intellectual enrichment protects against decline in cognitive efficiency and memory. Consideration of these protective factors should improve prediction of future cognitive decline in patients with MS.
Authors: James F Sumowski; Nancy Chiaravalloti; David Erlanger; Tanya Kaushik; Ralph H B Benedict; John DeLuca Journal: Mult Scler Date: 2011-05-11 Impact factor: 6.312
Authors: Ralph H B Benedict; Sarah A Morrow; Bianca Weinstock Guttman; Diane Cookfair; David J Schretlen Journal: J Int Neuropsychol Soc Date: 2010-07-08 Impact factor: 2.892
Authors: James F Sumowski; Maria A Rocca; Victoria M Leavitt; Gianna Riccitelli; Giancarlo Comi; John DeLuca; Massimo Filippi Journal: Neurology Date: 2013-05-10 Impact factor: 9.910
Authors: Maria Pia Amato; Lorenzo Razzolini; Benedetta Goretti; Maria Laura Stromillo; Francesca Rossi; Antonio Giorgio; Bahia Hakiki; Marta Giannini; Luisa Pastò; Emilio Portaccio; Nicola De Stefano Journal: Neurology Date: 2013-04-10 Impact factor: 9.910
Authors: Maria Pia Amato; Dawn Langdon; Xavier Montalban; Ralph H B Benedict; John DeLuca; Lauren B Krupp; Alan J Thompson; Giancarlo Comi Journal: J Neurol Date: 2012-11-23 Impact factor: 4.849
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: J F Sumowski; M A Rocca; V M Leavitt; G Riccitelli; J Sandry; J DeLuca; G Comi; M Filippi Journal: Eur J Neurol Date: 2015-02-04 Impact factor: 6.089
Authors: James F Sumowski; Maria A Rocca; Victoria M Leavitt; Alessandro Meani; Sarlota Mesaros; Jelena Drulovic; Paolo Preziosa; Christian G Habeck; Massimo Filippi Journal: Neurology Date: 2016-04-27 Impact factor: 9.910
Authors: Sylvia Klineova; Rachel Brandstadter; Michelle T Fabian; Ilana Katz Sand; Stephen Krieger; Victoria M Leavitt; Christina Lewis; Claire S Riley; Fred Lublin; Aaron E Miller; James F Sumowski Journal: Mult Scler Date: 2019-06-07 Impact factor: 6.312
Authors: Markus D Schirmer; Mark R Etherton Md PhD; Adrian V Dalca PhD; Anne-Katrin Giese Md; Lisa Cloonan MSc; Ona Wu PhD; Polina Golland PhD; Natalia S Rost Md Mph Faan Journal: J Stroke Cerebrovasc Dis Date: 2018-09-28 Impact factor: 2.136
Authors: Tom A Fuchs; Michael G Dwyer; Amy Kuceyeski; Sanjeevani Choudhery; Keith Carolus; Xian Li; Matthew Mallory; Bianca Weinstock-Guttman; Dejan Jakimovski; Deepa Ramasamy; Robert Zivadinov; Ralph H B Benedict Journal: Hum Brain Mapp Date: 2018-05-08 Impact factor: 5.038
Authors: Carolyn E Schwartz; Wesley Michael; Jie Zhang; Bruce D Rapkin; Mirjam A G Sprangers Journal: Qual Life Res Date: 2017-09-06 Impact factor: 4.147